Yarrow Bioscience (YARW) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $20.00, +5.82% vs the prior close of $18.90.
- Volume 183.60K shares, 1.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
YARW jumps 5.8% to $20.00. Closed at $20.00, +5.82% vs the prior close of $18.90. Day range $18.84–$20.05, opened at $18.85.
YARW daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — YARW jumps 5.8% to $20.00
- Closed at $20.00, +5.82% vs the prior close of $18.90. Day range $18.84–$20.05, opened at $18.85.
- Volume was 183.60K shares, 1.8x its 50-day average of 103.14K.
- Price is -34.2% vs its 50-day average ($30.39) and -36.0% vs its 200-day average ($31.24).
- 52-week range $16.05–$46.95; today's close sits at 13% of that range, 57.4% below the 52-week high.
Oct 14, 2026 — YARW rises 1.6% to $18.90
- Closed at $18.90, +1.61% vs the prior close of $18.60. Day range $18.16–$19.66, opened at $18.56.
- Volume was 105.60K shares, 1.0x its 50-day average of 101.82K.
- Price is -38.5% vs its 50-day average ($30.75) and -39.6% vs its 200-day average ($31.28).
- 52-week range $16.05–$46.95; today's close sits at 9% of that range, 59.7% below the 52-week high.
Oct 13, 2026 — YARW slides 6.2% to $18.60, a 6-month low
- Closed at $18.60, -6.16% vs the prior close of $19.82. Day range $18.40–$20.16, opened at $19.84.
- Volume was 99.80K shares, 1.0x its 50-day average of 100.15K.
- Price is -40.2% vs its 50-day average ($31.13) and -40.6% vs its 200-day average ($31.34).
- 52-week range $16.05–$46.95; today's close sits at 8% of that range, 60.4% below the 52-week high.
Oct 12, 2026 — YARW rises 0.6% to $19.82
- Closed at $19.82, +0.56% vs the prior close of $19.71. Day range $19.36–$20.50, opened at $19.74.
- Volume was 88.60K shares, 0.9x its 50-day average of 98.75K.
- Price is -36.9% vs its 50-day average ($31.43) and -36.9% vs its 200-day average ($31.39).
- 52-week range $16.05–$46.95; today's close sits at 12% of that range, 57.8% below the 52-week high.
Oct 9, 2026 — YARW dips 0.8% to $19.71
- Closed at $19.71, -0.81% vs the prior close of $19.87. Day range $19.39–$20.94, opened at $20.94.
- Volume was 162.20K shares, 1.7x its 50-day average of 95.94K.
- Price is -37.9% vs its 50-day average ($31.73) and -37.3% vs its 200-day average ($31.43).
- 52-week range $16.05–$46.95; today's close sits at 12% of that range, 58.0% below the 52-week high.
Oct 8, 2026 — YARW jumps 5.8% to $19.87
- Closed at $19.87, +5.83% vs the prior close of $18.77. Day range $18.33–$20.32, opened at $18.96.
- Volume was 94.80K shares, 1.0x its 50-day average of 94.36K.
- Price is -37.9% vs its 50-day average ($32.00) and -36.9% vs its 200-day average ($31.48).
- 52-week range $16.05–$46.95; today's close sits at 12% of that range, 57.7% below the 52-week high.
Oct 7, 2026 — YARW ends flat (+0.2%) to $18.77
- Closed at $18.77, +0.24% vs the prior close of $18.73. Day range $18.24–$20.90, opened at $18.67.
- Volume was 140.50K shares, 1.5x its 50-day average of 92.11K.
- Price is -41.7% vs its 50-day average ($32.21) and -40.4% vs its 200-day average ($31.52).
- 52-week range $16.05–$46.95; today's close sits at 9% of that range, 60.0% below the 52-week high.
Oct 6, 2026 — YARW slides 7.7% to $18.73, a 6-month low, 3 down days in a row
- Closed at $18.73, -7.73% vs the prior close of $20.30. Day range $18.53–$21.08, opened at $20.14.
- Volume was 69.20K shares, 0.7x its 50-day average of 92.60K.
- Price is -42.2% vs its 50-day average ($32.39) and -40.7% vs its 200-day average ($31.58).
- 52-week range $16.05–$46.95; today's close sits at 9% of that range, 60.1% below the 52-week high.
- That makes 3 straight losses.
Oct 5, 2026 — YARW slides 8.8% to $20.30, a 6-month low
- Closed at $20.30, -8.85% vs the prior close of $22.27. Day range $19.53–$22.00, opened at $21.80.
- Volume was 102.50K shares, 1.1x its 50-day average of 91.73K.
- Price is -37.7% vs its 50-day average ($32.59) and -35.8% vs its 200-day average ($31.63).
- 52-week range $16.00–$46.95; today's close sits at 14% of that range, 56.8% below the 52-week high.
Oct 2, 2026 — YARW slides 5.6% to $22.27, a 6-month low
- Closed at $22.27, -5.64% vs the prior close of $23.60. Day range $22.19–$23.92, opened at $23.59.
- Volume was 66.10K shares, 0.7x its 50-day average of 90.80K.
- Price is -31.9% vs its 50-day average ($32.69) and -29.6% vs its 200-day average ($31.63).
- 52-week range $16.00–$46.95; today's close sits at 20% of that range, 52.6% below the 52-week high.
YARW latest news & SEC filings
Every SEC filing by or about YARW in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 17, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Sep 11, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 11, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 19, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form POS AM — POS AM filing
POS AM filing
Aug 13, 2026 · Form 8-K/A — Current report (amended)
Amended current report
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $97.00K (prior year $69.00K) (+40.6% vs Jun 30, 2025)
- Net income: -$3.01M (prior year -$5.75M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$3.51 (prior year -$6.73) (loss narrowed vs Jun 30, 2025)
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade YARW
- Last results release: Jul 28, 2026 (8-K Item 2.02). Previous ones: Nov 6, 2025, Aug 14, 2025, Jul 30, 2025. Based on that rhythm, the next report is likely around Oct 27, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.10% (largest 8.8%). That is a volatile stock.
- Liquidity: about 131.00K shares (≈$2.62M) trade per day on average.
- 52-week position: $20.00 vs a range of $16.05–$46.95 (13% of the range).
- Dividends: last ex-dividend date Jul 24, 2026 ($20.1/share); 1 payments in the past 12 months.
- Splits: 1:50 on Jul 27, 2026
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Sep 14, 2026; 8-K Sep 10, 2026; 10-Q Aug 13, 2026.
- Share count: 2.67M shares outstanding (Aug 10, 2026), -89.5% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
YARW market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 18.85 | 20.05 | 18.84 | 20.00 | 183.60K |
| Oct 14, 2026 | 18.56 | 19.66 | 18.16 | 18.90 | 105.60K |
| Oct 13, 2026 | 19.84 | 20.16 | 18.40 | 18.60 | 99.80K |
| Oct 12, 2026 | 19.74 | 20.50 | 19.36 | 19.82 | 88.60K |
| Oct 9, 2026 | 20.94 | 20.94 | 19.39 | 19.71 | 162.20K |
| Oct 8, 2026 | 18.96 | 20.32 | 18.33 | 19.87 | 94.80K |
| Oct 7, 2026 | 18.67 | 20.90 | 18.24 | 18.77 | 140.50K |
| Oct 6, 2026 | 20.14 | 21.08 | 18.53 | 18.73 | 69.20K |
| Oct 5, 2026 | 21.80 | 22.00 | 19.53 | 20.30 | 102.50K |
| Oct 2, 2026 | 23.59 | 23.92 | 22.19 | 22.27 | 66.10K |
| Oct 1, 2026 | 22.49 | 24.10 | 22.49 | 23.60 | 35.40K |
| Sep 30, 2026 | 24.28 | 24.63 | 21.49 | 22.52 | 105.70K |
| Sep 29, 2026 | 24.18 | 25.08 | 23.87 | 24.19 | 100.60K |
| Sep 28, 2026 | 25.47 | 25.50 | 23.68 | 24.00 | 107.70K |
| Sep 25, 2026 | 26.98 | 27.13 | 25.01 | 25.54 | 474.20K |
| Sep 24, 2026 | 27.79 | 27.96 | 25.73 | 26.07 | 183.90K |
| Sep 23, 2026 | 28.74 | 28.95 | 27.29 | 27.88 | 102.30K |
| Sep 22, 2026 | 28.81 | 29.00 | 27.76 | 28.68 | 104.80K |
| Sep 21, 2026 | 29.88 | 30.02 | 27.83 | 28.30 | 136.00K |
| Sep 18, 2026 | 30.05 | 32.04 | 29.00 | 29.29 | 156.50K |
About Yarrow Bioscience
Yarrow Bioscience (YARW) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NEW HAVEN, CT. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1566044.
YARW board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Mona Ashiya | Director | Jul 29, 2026 |
| Sharon Barbari | Director | Dec 15, 2025 |
| Steven L Basta | Director | Dec 15, 2025 |
| David Domzalski | PRESIDENT AND CEO | Jul 24, 2026 |
| Rebecca Frey | Chief Executive Officer | Jul 29, 2026 |
| Steven L. Hoerter | Director | Jul 29, 2026 |
| Patrick G Lepore | Director | Dec 15, 2025 |
| Elisabeth Sandoval Little | Director | Dec 15, 2025 |
| Sven Ante Lundberg | Director | Jul 29, 2026 |
| Advisors Llc Orbimed | Director | Jul 29, 2026 |
| Capital Gp X Llc Orbimed | Director | Jul 29, 2026 |
| Genesis Gp Llc Orbimed | Director | Jul 29, 2026 |
| Peter B. Silverman | Director | Jul 29, 2026 |
| William Richard White | Director | Jul 29, 2026 |
| Tyler Zeronda | Director | Jul 29, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Rachael Alford | Chief Operating Officer | Jul 29, 2026 |
| David Domzalski | PRESIDENT AND CEO | Jul 24, 2026 |
| Rebecca Frey | Chief Executive Officer | Jul 29, 2026 |
| Mutya Harsch | CHIEF LEGAL OFFICER AND GC | Jul 24, 2026 |
| Lori Payton | Chief Development Officer | Jul 29, 2026 |
| Steven Ryder | Chief Medical Officer | Jul 29, 2026 |
| Iain Stuart | CHIEF SCIENTIFIC OFFICER | Jul 24, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
YARW financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $570.00K | $-26.48M | -0.62 | $-33.12M |
| Dec 31, 2024 | $501.00K | $-39.83M | -0.93 | $-33.97M |
| Dec 31, 2023 | $424.00K | $-28.45M | -2.78 | $-25.34M |
| Dec 31, 2022 | $477.00K | $-23.21M | -7.28 | $-29.20M |
| Dec 31, 2021 | $931.00K | $-73.33M | -25.64 | $-56.37M |
Latest balance sheet: total assets $23.60M, total liabilities $1.54M, cash $22.93M (as of Jun 30, 2026).
YARW earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 28, 2026 | 8-K Item 2.02 (results) | $28.05 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $17.65 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $17.50 |
| Jul 30, 2025 | 8-K Item 2.02 (results) | $19.90 |
| May 8, 2025 | 8-K Item 2.02 (results) | $65.00 |
| Mar 6, 2025 | 8-K Item 2.02 (results) | $116.50 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $157.75 |
| Aug 14, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Feb 29, 2024 | 8-K Item 2.02 (results) | — |
| Nov 13, 2023 | 8-K Item 2.02 (results) | — |
| Oct 30, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on YARW
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.